Sentences with phrase «chronic lymphocytic leukemia»

A series of preliminary Mayo Clinic studies conducted in 2010 showed promise for the potential use of a chemical component of green tea (epigallocatechin gallate) in reducing the number of cancer cells in patients with chronic lymphocytic leukemia.

Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.

Venetoclax has durable clinical activity in patients with relapsed / refractory chronic lymphocytic leukemia whose disease progressed during or after ibrutinib therapy.

No improvement in long - term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets # 1 and # 2 treated with chemo (immuno) therapy

Researchers will identify potential treatment targets for B - cell chronic lymphocytic leukemia in dogs and ways to identify high - risk patients.

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down - regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells

Auranofin is now in clinical trials for treating chronic lymphocytic leukemia.

As chronic lymphocytic leukemia progresses slowly, some dogs can go on without chemotherapy for up to 2 years.

Auranofin is being evaluated by The Learning Collaborative as a treatment for relapsed chronic lymphocytic leukemia (CLL).

Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.

As a long time chronic lymphocytic leukemia (CLL) cancer patient, Marty Smith has every reason to be bullish on cancer.

Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high - risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center (ACC).

Several types of leukemia were characterized by exome sequencing, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute monocytic leukemia (M5 AML), and pediatric acute lymphocytic leukemia (ALL).

The lab chose to use the TCL1 mouse model to study B - cell leukemia because ~ 90 percent of human chronic lymphocytic leukemia (CLL) patients express the TCL1 protein, and the overexpression of TCL1 in B cells leads to the development of CLL in mice.

Another team used personalized cellular therapy to cure chronic lymphocytic leukemia in patients.

If chronic lymphocytic leukemia patients with a good or poor prognosis could be identified already at the time of diagnosis, physicians would have better possibilities to adjust their therapeutic and follow - up strategies.

Jimenez de Oya N *, De Giovanni M *, Fioravanti J, Ubelhart R, Di Lucia P, Fiocchi A, Iacovelli S, Efremov DG, Caligaris - Cappio F, Jumaa H, Ghia P, Guidotti LG, Iannacone M. Pathogen - specific B cell receptors drive chronic lymphocytic leukemia by light chain - dependent cross-reaction with autoantigens.

In other trials, it was found that Green Tea extract could arrest the growth of cancer cells in people suffering from chronic lymphocytic leukemia (CLL).

When lymphoblasts develop slowly, the condition is called chronic lymphocytic leukemia (CLL).

Cassie developed Chronic Lymphocytic Leukemia (CLL) at the age of eight.

To examine cancer - specific stress at treatment initiation as a predictor of psychological and physical functioning trajectories in patients with relapsed / refractory chronic lymphocytic leukemia during the first 5 months of treatment.

David was diagnosed with chronic lymphocytic leukemia (CLL), and chose to heal his body naturally.

The U.S. Food and Drug Administration (FDA) approved fludarabine for treating chronic lymphocytic leukemia (CCL).

A Phase 1b, Open - Label, Dose Escalation Study of ME - 401 in Subjects with Relapsed / Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL / SLL) or Follicular Lymphoma (FL)

By employing a translational approach and utilizing cutting - edge molecular tools, his research group has made outstanding contributions to our understanding of the mechanisms behind the development of chronic lymphocytic leukemia (CLL), the most common adult leukemia.

The authors conclude that FL118 - based therapy may be beneficial for a subgroup of cancer patients with tumors such as chronic lymphocytic leukemia and melanomas, in which MdmX overexpression confers treatment resistance.

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia; John C. Byrd, MD, The Ohio State University.

The assessment of TP53 mutational status is becoming a routine clinical practice for chronic lymphocytic leukemia patients (CLL).

Prognostic Value of ZAP - 70 Expression in Chronic Lymphocytic Leukemia as Assessed by Quantitative Polymerase Chain Reaction and Flow Cytometry.

Mohle R, Failenschmid C, Bautz F, Kanz L. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell - derived factor - 1 (SDF - 1).

In particular, it is working on two drugs that target blood cancer therapies for non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

The drug treats chronic lymphocytic leukemia (CLL) and the drug is showing promise of moving up the treatment line to a front - line position where the market potential is even larger.

However, chronic lymphocytic leukemia (CLL), which is more common in the elderly, is difficult to cure, although long - term survival has been achieved in chronic myeloid leukemia due to the introduction of tyrosine kinase inhibitors (drugs that block signals promoting cancer cell growth).

In addition to ALL, asparaginase is also used to treat rarer cancers such as lymphosarcoma, Hodgkin's disease, chronic lymphocytic leukemia, reticulosarcoma and melanosarcoma.

About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study published online by JAMA Oncology.

Lymphoid cancers include diffuse large B - cell lymphomas (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL), which were the focus of the present study.

«Reasons for ibrutinib therapy discontinuation in patients with chronic lymphocytic leukemia.»

Ibrutinib has been approved by the U.S. Food and Drug Administration for the treatment of certain patients with several other cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström macroglobulinemia.

A year later, Carlo Croce, now director of the Human Cancer Genetics Program at Ohio State University, reported that chronic lymphocytic leukemia (CLL), the most common form of the disease, was caused by deletion of two microRNA genes.

«We have seen SF3B1 mutation in chronic lymphocytic leukemia and in myeloid dysplastic disorders, and now we show its importance in mucosal melanoma,» says Aik Choon Tan, PhD, investigator at the CU Cancer Center and associate professor of Bioinformatics at the CU School of Medicine.

Patients who have enrolled in trials of this approach for acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) typically undergo lymphodepleting chemotherapy before receiving an infusion of their newly engineered cells.

The new drug will now be tested in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma in an early stage clinical trial.

The findings will be presented by Stephen Schuster, MD, the Robert and Margarita Louis - Dreyfus Associate Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research in the Abramson Cancer Center.

In a dose - optimization study of 35 patients with chronic lymphocytic leukemia (CLL), researchers examined two different doses of CTL019 — a lower dose (5 x 107 cells) and a higher dose (5 x 108 cells).

Notch is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the United States.

Some other lncRNAs have been found at higher levels in breast, stomach, lung, prostate cancer and chronic lymphocytic leukemia.

Levine and his colleagues designed a new gene that can be inserted into T cells to trick them into attacking cancerous B cells, the cause of chronic lymphocytic leukemia (CLL).

Chronic lymphocytic leukemia (CLL) is a malignancy characterized by the progressive accumulation of mature B cells.